Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by nemo3on Mar 09, 2019 10:08am
160 Views
Post# 29465019

RE:RE:RE:PH2 CANDIAN PATIENT TREATMENT PENDING REB. CTA/ITA COMPLETE

RE:RE:RE:PH2 CANDIAN PATIENT TREATMENT PENDING REB. CTA/ITA COMPLETEI look forward to TLT moving forward with this clinical trial Ph 2.  I am hopeful they actually get this trial going soon and in 2019 but we are well into March already. So we might not see 6 month data until mid 2020 or later depending on when this trial actually starts...For me, the 6 month data will show everyone the efficacy of this treatment with more confidence at 6 months than 3 months. I base this on the 1 patient of 3 at the full dose who had metastasized before 6 months which may or may not have been to cancer cells undetected in this patient at 90 days.
Bullboard Posts